Navigation Links
Resverlogix Scientific Data Presented at EAS Congress
Date:6/22/2010

New data from Phase 1b/2a trial included

TSX Exchange Symbol: RVX

HAMBURG, Germany and CALGARY, AB, June 22 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference being held in Hamburg, Germany. The presentation titled "RVX-208 given orally raises plasma ApoA-I and HDL in human clinical trials," was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.

"The data presented in Germany today further highlights that patients with low HDL/Apo-Al benefit most. For those patients in the highest risk category, subjects with low baseline HDL/Apo-Al, our data demonstrated that RVX-208 increased plasma levels of Apo-Al in the order of 13.25% compared to placebo. This data, combined with similar low baseline HDL/Apo A-l data analysis of the upcoming ASSERT trial data will further support the design of a very effective and efficient ASSURE trial," said Donald J. McCaffrey, President & CEO of Resverlogix.

Resverlogix recently completed a Phase 2 clinical trial called ASSERT to study RVX-208 an oral small molecule therapy for the treatment of atherosclerosis. The ASSERT trial enrolled subjects with stable coronary artery disease. A second planned Phase 2 trial, designated ASSURE, will include subjects with acute coronary syndrome and coronary artery disease of whom all will be examined with intravascular ultrasound (IVUS). Both the ASSERT and ASSURE
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Completes Dosing for ASSERT Trial
2. Resverlogix Notice of Conference Call & Webcast for Year End Update
3. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
4. Resverlogix Completes Patient Recruitment for ASSERT Trial
5. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
6. Resverlogix Presenting at Biotech Showcase
7. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
8. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
9. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
10. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
11. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Alba Therapeutics Corporation today,announced that its Investigational New ... endogenous insulin production capacity in new-onset,type 1 diabetes ... period,by the U.S. Food and Drug Administration (FDA). ... in 2008 while focusing the majority,of its development ...
... Sept. 5 Thermo Fisher,Scientific Inc. (NYSE: ... has,acquired the instrument sales business of Davis Inotek ... Instruments and excludes its,related calibration services. Davis Instruments ... control instruments, serving customers in a,wide range of ...
... A study in the August 2007,issue of ... GlycoMark,1,5-anhydroglucitol (1,5-AG) blood test to evaluate therapy ... hyperglycemia (elevated,after-meal glucose levels). Controlling after-meal glucose ... and reducing the burden of,cardiovascular complications, the ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes 2
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... cancer patients with high levels of vitamin D in their ... shows. , Patients with the highest levels of vitamin ... with the lowest levels, the findings reveal. , The study ... D in bowel cancer patients after their diagnosis which ... from dietary sources with their long term survival prospects. ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... Mental Health (CAMH) is proud to announce a landmark ... Innovation (CFI) into research that will propel the understanding, ... to the next level of excellence. This ... Research Hospital Fund will allow CAMH to leverage our ...
... new study in the September issue of the Journal ... may have a role in the rising rate of diabetes, ... , DNA is the primary mechanism of inheritance; kids get ... scientists are just starting to understand additional kinds of inheritance ...
... invasion of unwanted species, according to a recent U.S. ... the reef and eliminate all the native coral, dramatically ... This study documents for the first time that a ... reef is unambiguously associated with man-made structures. ...
Cached Biology News:Large-scale investment catapults CAMH's mental illness and addiction research forward 2Shipwrecks on coral reefs harbor unwanted species 2
Recombinant Equine IL-6...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: